Literature DB >> 2439838

Central and regional vascular hemodynamics following intravenous milrinone in the conscious rat: comparison with dobutamine.

H Drexler, S Höing, F Faude, H Wollschläger, H Just.   

Abstract

This study examined the hemodynamic and regional vascular profile of intravenous (i.v.) milrinone during increasing doses (3, 6, 12 micrograms/kg/min, n = 8) and by intraindividual comparison of milrinone and dobutamine (n = 10) in normal conscious rats. At 3 micrograms/kg/min, Milrinone increased coronary and cerebral blood flow (radioactive microspheres 15 +/- 5 microns) (7.7-9.8 and 1.05-1.27 ml/min/g respectively, both p less than 0.05) without significant changes in systemic hemodynamics. At 6 micrograms/kg/min milrinone increased skeletal muscle blood flow (0.19-0.24 ml/min/g, p less than 0.05) along with increases in cardiac output, stroke volume, and stroke work (all p less than 0.05), while systemic vascular resistance decreased (-51%, p less than 0.05). When compared with dobutamine, milrinone caused a greater increase in cardiac output (+26% vs. +17%) and a greater reduction in systemic vascular resistance. Milrinone and dobutamine increased renal, intestinal, cerebral, and coronary flow to a similar extent, but only milrinone enhanced hepatic arterial blood flow (+26%, p less than 0.05) and tended to increase flow to skeletal muscle (+35%, p = 0.07). We conclude that milrinone exerts significant regional vasodilating effects in a conscious rat model, being most prominent in the coronary and cerebral circulations at a dosage that does not alter central hemodynamics. At higher doses, milrinone causes a balanced increase in regional blood flow including enhanced flow to skeletal muscle. The hemodynamic (particularly as compared with dobutamine) and regional vascular profile of milrinone suggests a predominant vasodilating effect in the rat. Given a similar limited response of rat and diseased human myocardium to milrinone, these findings may have important clinical implications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439838     DOI: 10.1097/00005344-198705000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.

Authors:  P S Pagel; D A Hettrick; D C Warltier
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  Amrinone improves postischemic myocardial metabolism in the rat heart-lung preparation.

Authors:  Masaki Kume; Satoshi Kashimoto; Atsusi Furuya; Teruo Kumazawa
Journal:  J Anesth       Date:  1996-12       Impact factor: 2.078

3.  Differential effects of (+/-)-dobutamine and human alpha-CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett; B Hughes; R Foulkes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

4.  Intravenous milrinone for treatment of delayed cerebral ischaemia following subarachnoid haemorrhage: a pooled systematic review.

Authors:  Mendel Castle-Kirszbaum; Leon Lai; Julian Maingard; Hamed Asadi; R Andrew Danks; Tony Goldschlager; Ronil V Chandra
Journal:  Neurosurg Rev       Date:  2021-03-08       Impact factor: 3.042

5.  Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.

Authors:  Aimee L Brame; Janet J Maguire; Peiran Yang; Alex Dyson; Rubben Torella; Joseph Cheriyan; Mervyn Singer; Robert C Glen; Ian B Wilkinson; Anthony P Davenport
Journal:  Hypertension       Date:  2015-02-23       Impact factor: 10.190

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.